What is the equity of MaxCyte this year?
MaxCyte has equity of 232.17 M USD this year.
MaxCyte Equity 2024
MaxCyte Equity
232.17 M USD
Ticker
MXCT
ISIN
US57777K1060
WKN
A2AGVE
In 2024, MaxCyte's equity was 232.17 M USD, a -8.6% increase from the 254 M USD equity in the previous year.
MaxCyte Aktienanalyse
What does MaxCyte do?
MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing MaxCyte's Equity
MaxCyte's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MaxCyte's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating MaxCyte's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
MaxCyte's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in MaxCyte’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about MaxCyte Stock
What was the equity of MaxCyte compared to the previous year?
The equity of MaxCyte has increased/decreased by -8.6% decreased compared to the previous year.
What impact does a high equity have on investors of MaxCyte?
A high equity is advantageous for investors of MaxCyte as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of MaxCyte?
A low equity can be a risk for investors of MaxCyte, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of MaxCyte affect the company?
An increase in equity of MaxCyte can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of MaxCyte affect the company?
A reduction in equity of MaxCyte can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of MaxCyte?
Some factors that can affect the equity of MaxCyte include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of MaxCyte so important for investors?
The equity of MaxCyte is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can MaxCyte take to change the equity?
To change equity, MaxCyte can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does MaxCyte pay?
Over the past 12 months, MaxCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MaxCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of MaxCyte?
The current dividend yield of MaxCyte is .
When does MaxCyte pay dividends?
MaxCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MaxCyte?
MaxCyte paid dividends every year for the past 0 years.
What is the dividend of MaxCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MaxCyte located?
MaxCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von MaxCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MaxCyte from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.
When did MaxCyte pay the last dividend?
The last dividend was paid out on 6/28/2024.
What was the dividend of MaxCyte in the year 2023?
In the year 2023, MaxCyte distributed 0 USD as dividends.
In which currency does MaxCyte pay out the dividend?
The dividends of MaxCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von MaxCyte
Our stock analysis for MaxCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MaxCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.